MSD fined $125k for code breach
Following a complaint by competitor AstraZeneca, the Medicines Australia Code of Conduct Committee found MSD’s use of the claim “Now with patient outcomes data” in promotional materials was a breach of the code.
AstraZeneca argued the claim constituted promotion of Vytorin for the reduction of cardiovascular events, which is not an approved indication. The phrase referred to a clinical trial of 9000 patients with advanced chronic kidney disease (CKD). The primary endpoint was reached, with researchers concluding the reduction of LDL cholesterol with simvastatin